– Second-Quarter Revenue of $1.06 Billion
–
– Second-Quarter GAAP Earnings per Share of
$1.89 and Non-GAAP Earnings per Share of $2.69 –
– Updates 2023 Guidance –
Charles River Laboratories International, Inc. (NYSE: CRL) today
reported its results for the second quarter of 2023. For the
quarter, revenue was $1.06 billion, an increase of 8.9% from $973.1
million in the second quarter of 2022.
Acquisitions contributed 0.2% to consolidated second-quarter
revenue growth. The divestiture of the Avian Vaccine business in
December 2022 reduced reported revenue growth by 2.3%, and the
impact of foreign currency translation reduced reported revenue
growth by 0.2% for the quarter. Excluding the effect of these
items, organic revenue growth of 11.2% was driven primarily by the
Research Models and Services (RMS) and Discovery and Safety
Assessment (DSA) business segments.
On a GAAP basis, second-quarter net income attributable to
common shareholders was $97.0 million, a decrease of 11.3% from
$109.3 million for the same period in 2022. Second-quarter diluted
earnings per share on a GAAP basis were $1.89, a decrease of 11.3%
from $2.13 for the second quarter of 2022. GAAP earnings per share
included a loss from the Company’s venture capital and other
strategic investments of $0.03 per share in the second quarter of
2023, compared to a loss of $0.14 per share for the same period in
2022. Certain venture capital and other strategic investment
performance has been excluded from the Company’s non-GAAP
results.
On a non-GAAP basis, net income was $138.3 million for the
second quarter of 2023, a decrease of 2.5% from $141.9 million for
the same period in 2022. Second-quarter diluted earnings per share
on a non-GAAP basis were $2.69, a decrease of 2.9% from $2.77 per
share for the second quarter of 2022.
The lower GAAP and non-GAAP net income and earnings per share
were driven primarily by non-operating items, including increased
interest expense and a higher tax rate, as well as the impact of
the Avian Vaccine divestiture.
James C. Foster, Chairman, President and Chief Executive
Officer, said, “We were pleased with our second-quarter financial
results, highlighted by another strong quarter for the DSA segment
and the expected improvement in the RMS and Manufacturing segments.
We believe our significant scientific breadth and experience, as
well as the substantial scale and duration of our DSA backlog, are
important differentiators during times of macroeconomic or funding
uncertainty.”
“We are also closely monitoring the near-term demand trends that
show more cautious spending by biopharmaceutical clients. In this
environment, we believe clients will look for scientific partners
who can provide even more efficiency and speed to market, and that
they will continue to choose Charles River in order to derive
additional value through our flexible and efficient outsourcing
solutions. We believe these factors will enable us to effectively
manage the business and give us confidence in our revenue growth
and non-GAAP earnings per share guidance for the year, which we are
narrowing to the upper ends of the previous ranges,” Mr. Foster
concluded.
Second-Quarter Segment
Results
Research Models and Services (RMS)
Revenue for the RMS segment was $209.9 million in the second
quarter of 2023, an increase of 12.6% from $186.4 million in the
second quarter of 2022. The impact of foreign currency translation
reduced revenue by 1.3% in the quarter. Organic revenue growth of
13.9% was driven by broad-based growth for research models in all
geographies, particularly in China, as well as for research model
services, primarily the Insourcing Solutions (IS) business.
In the second quarter of 2023, the RMS segment’s GAAP operating
margin increased to 23.3% from 21.2% in the second quarter of 2022,
and on a non-GAAP basis, the operating margin increased to 26.4%
from 24.9%. The GAAP and non-GAAP operating margin increases were
driven primarily by the timing of large model shipments in
China.
Discovery and Safety Assessment (DSA)
Revenue for the DSA segment was $663.5 million in the second
quarter of 2023, an increase of 12.1% from $591.9 million in the
second quarter of 2022. The SAMDI Tech acquisition contributed 0.3%
to reported DSA revenue growth, and the impact of foreign currency
translation was negligible in the quarter. Organic revenue growth
of 11.7% was driven by the Safety Assessment business, as a result
of higher pricing and study volume.
In the second quarter of 2023, the DSA segment’s GAAP operating
margin increased to 24.3% from 21.8% in the second quarter of 2022,
and on a non-GAAP basis, the operating margin increased to 27.6%
from 25.3%. The GAAP and non-GAAP operating margin increases were
driven by operating leverage from higher revenue in the Safety
Assessment business.
Manufacturing Solutions (Manufacturing)
Revenue for the Manufacturing segment was $186.5 million in the
second quarter of 2023, a decrease of 4.2% from $194.8 million in
the second quarter of 2022. The impact of the Avian Vaccine
divestiture reduced revenue by 10.8%, and the impact of foreign
currency translation was negligible. Organic revenue growth of 6.6%
for the quarter was driven primarily by the CDMO and Microbial
Solutions businesses.
In the second quarter of 2023, the Manufacturing segment’s GAAP
operating margin decreased to 13.1% from 32.1% in the second
quarter of 2022, and on a non-GAAP basis, the operating margin
decreased to 22.9% from 28.6% in the second quarter of 2022. The
GAAP and non-GAAP operating margin declines were primarily the
result of lower operating margins in the Biologics Testing and CDMO
businesses. The GAAP operating margin decline was also driven by an
acquisition-related adjustment in the CDMO business that benefited
second-quarter 2022 results.
Updates 2023 Guidance
The Company is updating its 2023 financial guidance, which was
previously provided on May 11, 2023. The Company is narrowing its
revenue growth and non-GAAP earnings per share outlooks to largely
reflect its solid first-half financial performance and the
successful implementation of mitigation efforts around NHP supply
constraints. These benefits are anticipated to be partially offset
by near-term demand trends as biopharmaceutical clients appear to
be reprioritizing their pipelines and tightening R&D
budgets.
The Company’s 2023 guidance for revenue growth and earnings per
share is as follows:
2023 GUIDANCE
CURRENT
PRIOR
Revenue growth, reported
2.5% – 4.5%
2.0% – 4.5%
Impact of divestitures/(acquisitions),
net
~1.5%
~1.5%
Impact of 53rd week in 2022
~1.5%
~1.5%
Unfavorable/(favorable) impact of foreign
exchange
0.0% - (0.5)%
0.0% - (0.5)%
Revenue growth, organic (1)
5.5% – 7.5%
5.0% – 7.5%
GAAP EPS estimate
$7.60 – $8.20
$7.45 – $8.45
Acquisition-related amortization
~$2.00
~$2.00
Acquisition and integration-related
adjustments (2)
$0.20 – $0.25
~$0.10
Venture capital and other strategic
investment losses/(gains), net (3)
$0.06
$0.03
Other items (4)
~$0.40
$0.30 – $0.35
Non-GAAP EPS estimate
$10.30 – $10.90
$9.90 – $10.90
Footnotes to
Guidance Table:
(1) Organic revenue growth is defined as
reported revenue growth adjusted for completed acquisitions and
divestitures, the 53rd week in 2022, and foreign currency
translation.
(2) These adjustments are related to the
evaluation and integration of acquisitions and divestitures, and
primarily include transaction, advisory, certain third-party
integration costs, and certain costs associated with
acquisition-related efficiency initiatives.
(3) Venture capital and other strategic
investment performance only includes recognized gains or losses on
certain investments. The Company does not forecast the future
performance of these investments.
(4) These items primarily relate to
charges associated with U.S. and international tax legislation that
necessitated changes to the Company’s international financing
structure; certain third-party legal costs related to (a)
environmental litigation related to the Microbial Solutions
business and (b) investigations by the U.S. government into the NHP
supply chain related to our Safety Assessment business; and (c)
severance and other costs related to the Company’s efficiency
initiatives.
Webcast
Charles River has scheduled a live webcast on Wednesday, August
9th, at 8:30 a.m. ET to discuss matters relating to this press
release. To participate, please go to ir.criver.com and select the
webcast link. You can also find the associated slide presentation
and reconciliations of GAAP financial measures to non-GAAP
financial measures on the website.
Investor Day
Charles River will host a virtual Meeting with Management on
Thursday, September 21st, beginning at 8:30 a.m. ET. Investors will
have the opportunity to listen to a webcast of the virtual event
through the Investor Relations section of the Company's website at
ir.criver.com. A replay will be accessible through the same
website.
Non-GAAP Reconciliations
The Company reports non-GAAP results in this press release,
which exclude often-one-time charges and other items that are
outside of normal operations. A reconciliation of GAAP to non-GAAP
results is provided in the schedules at the end of this press
release.
Use of Non-GAAP Financial
Measures
This press release contains non-GAAP financial measures, such as
non-GAAP earnings per diluted share, non-GAAP operating income,
non-GAAP operating margin, and non-GAAP net income. Non-GAAP
financial measures exclude, but are not limited to, the
amortization of intangible assets, and other charges and
adjustments related to our acquisitions and divestitures, including
the gain on our sale of our Avian Vaccine business; expenses
associated with evaluating and integrating acquisitions and
divestitures, including advisory fees and certain other
transaction-related costs, as well as fair value adjustments
associated with contingent consideration; charges, gains, and
losses attributable to businesses or properties we plan to close,
consolidate, or divest; severance and other costs associated with
our efficiency initiatives; the write-off of deferred financing
costs and fees related to debt financing; investment gains or
losses associated with our venture capital and other strategic
equity investments; certain legal costs in our Microbial Solutions
business related to environmental litigation and in our Safety
Assessment business related to U.S. government investigations into
the NHP supply chain; and adjustments related to the recognition of
deferred tax assets expected to be utilized as a result of changes
to the our international financing structure and the revaluation of
deferred tax liabilities as a result of foreign tax legislation.
This press release also refers to our revenue on both a GAAP and
non-GAAP basis: “organic revenue growth,” which we define as
reported revenue growth adjusted for foreign currency translation,
acquisitions, divestitures, and the impact of the 53rd week in
2022. We exclude these items from the non-GAAP financial measures
because they are outside our normal operations. There are
limitations in using non-GAAP financial measures, as they are not
presented in accordance with generally accepted accounting
principles, and may be different than non-GAAP financial measures
used by other companies. In particular, we believe that the
inclusion of supplementary non-GAAP financial measures in this
press release helps investors to gain a meaningful understanding of
our core operating results and future prospects without the effect
of these often-one-time charges, and is consistent with how
management measures and forecasts the Company's performance,
especially when comparing such results to prior periods or
forecasts. We believe that the financial impact of our acquisitions
and divestitures (and in certain cases, the evaluation of such
acquisitions and divestitures, whether or not ultimately
consummated) is often large relative to our overall financial
performance, which can adversely affect the comparability of our
results on a period-to-period basis. In addition, certain
activities and their underlying associated costs, such as business
acquisitions, generally occur periodically but on an unpredictable
basis. We calculate non-GAAP integration costs to include
third-party integration costs incurred post-acquisition. Presenting
revenue on an organic basis allows investors to measure our revenue
growth exclusive of acquisitions, divestitures, the 53rd week in
2022, and foreign currency exchange fluctuations more clearly.
Non-GAAP results also allow investors to compare the Company’s
operations against the financial results of other companies in the
industry who similarly provide non-GAAP results. The non-GAAP
financial measures included in this press release are not meant to
be considered superior to or a substitute for results of operations
presented in accordance with GAAP. The Company intends to continue
to assess the potential value of reporting non-GAAP results
consistent with applicable rules and regulations. Reconciliations
of the non-GAAP financial measures used in this press release to
the most directly comparable GAAP financial measures are set forth
in this press release, and can also be found on the Company’s
website at ir.criver.com.
Caution Concerning Forward-Looking
Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements may be identified by the use of
words such as “anticipate,” “believe,” “expect,” “intend,” “will,”
“would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and
other similar expressions that predict or indicate future events or
trends or that are not statements of historical matters. These
statements also include statements regarding Charles River’s
expectations regarding the availability of Cambodia-sourced NHPs;
the impact of the investigations by the U.S. Department of Justice
into the Cambodia NHP supply chain, including but not limited to
Charles River’s ability to cooperate fully with the U.S.
government; Charles River’s ability to effectively manage any
Cambodia NHP supply impact; the projected future financial
performance of Charles River and our specific businesses, including
our expectations with respect to the impact of NHP supply
constraints; earnings per share; client demand, particularly the
future demand for drug discovery and development products and
services, including our expectations for future revenue trends; our
expectations with respect to pricing of our products and services;
our expectations with respect to future tax rates and the impact of
such tax rates on our business; our expectations with respect to
the impact of acquisitions and divestitures completed in 2021,
2022, and 2023 on the Company, our service offerings, client
perception, strategic relationships, revenue, revenue growth rates,
revenue growth drivers, and earnings; the development and
performance of our services and products, including our investments
in our portfolio; market and industry conditions including the
outsourcing of services and identification of spending trends by
our clients and funding available to them; and Charles River’s
future performance as delineated in our forward-looking guidance,
and particularly our expectations with respect to revenue, the
impact of foreign exchange, interest rates, enhanced efficiency
initiatives. Forward-looking statements are based on Charles
River’s current expectations and beliefs, and involve a number of
risks and uncertainties that are difficult to predict and that
could cause actual results to differ materially from those stated
or implied by the forward-looking statements. Those risks and
uncertainties include, but are not limited to: NHP supply
constraints and the investigations by the U.S. Department of
Justice, including the impact on our projected future financial
performance, the timing of the resumption of Cambodia NHP imports,
our ability to manage supply impact, and potential study delays in
our Safety Assessment business attributable to NHP supply
constraints; changes and uncertainties in the global economy and
financial markets; the ability to successfully integrate businesses
we acquire; the timing and magnitude of our share repurchases;
negative trends in research and development spending, negative
trends in the level of outsourced services, or other cost reduction
actions by our clients; the ability to convert backlog to revenue;
special interest groups; contaminations; industry trends; new
displacement technologies; USDA and FDA regulations; changes in
law; continued availability of products and supplies; loss of key
personnel; interest rate and foreign currency exchange rate
fluctuations; changes in tax regulation and laws; changes in
generally accepted accounting principles; disruptions in the global
economy caused by the ongoing conflict between the Russian
federation and Ukraine; and any changes in business, political, or
economic conditions due to the threat of future terrorist activity
in the U.S. and other parts of the world, and related U.S. military
action overseas. A further description of these risks,
uncertainties, and other matters can be found in the Risk Factors
detailed in Charles River's Annual Report on Form 10-K as filed on
February 22, 2023, as well as other filings we make with the
Securities and Exchange Commission. Because forward-looking
statements involve risks and uncertainties, actual results and
events may differ materially from results and events currently
expected by Charles River, and Charles River assumes no obligation
and expressly disclaims any duty to update information contained in
this press release except as required by law.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SCHEDULE 1 CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED) (in thousands, except for per share data)
Three Months Ended Six Months Ended July 1,
2023 June 25, 2022 July 1, 2023 June 25,
2022 Service revenue
$
874,891
$
782,827
$
1,732,257
$
1,503,312
Product revenue
185,046
190,304
357,053
383,748
Total revenue
1,059,937
973,131
2,089,310
1,887,060
Costs and expenses: Cost of services provided (excluding
amortization of intangible assets)
578,099
522,623
1,143,576
1,009,487
Cost of products sold (excluding amortization of intangible assets)
82,861
93,782
169,103
184,029
Selling, general and administrative
199,758
131,711
374,604
281,744
Amortization of intangible assets
34,274
37,604
69,190
75,611
Operating income
164,945
187,411
332,837
336,189
Other income (expense): Interest income
1,426
188
2,232
315
Interest expense
(35,044
)
(3,703
)
(69,424
)
(13,137
)
Other expense, net
(2,663
)
(39,783
)
(5,940
)
(68,408
)
Income before income taxes
128,664
144,113
259,705
254,959
Provision for income taxes
29,221
33,449
56,308
49,069
Net income
99,443
110,664
203,397
205,890
Less: Net income attributable to noncontrolling interests
2,423
1,343
3,246
3,547
Net income attributable to common shareholders
$
97,020
$
109,321
$
200,151
$
202,343
Earnings per common share Net income attributable to common
shareholders: Basic
$
1.89
$
2.15
$
3.91
$
3.99
Diluted
$
1.89
$
2.13
$
3.90
$
3.94
Weighted-average number of common shares outstanding; Basic
51,216
50,823
51,157
50,732
Diluted
51,467
51,283
51,382
51,293
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SCHEDULE 2 CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED) (in thousands, except per share amounts)
July 1, 2023 December 31, 2022 Assets
Current assets: Cash and cash equivalents
$
200,445
$
233,912
Trade receivables and contract assets, net of allowances for credit
losses of $18,040 and $11,278, respectively
800,646
752,390
Inventories
285,280
255,809
Prepaid assets
105,020
89,341
Other current assets
113,389
107,580
Total current assets
1,504,780
1,439,032
Property, plant and equipment, net
1,529,640
1,465,655
Venture capital and strategic equity investments
300,281
311,602
Operating lease right-of-use assets, net
397,192
391,762
Goodwill
2,916,593
2,849,903
Intangible assets, net
929,890
955,275
Deferred tax assets
38,540
41,262
Other assets
155,465
148,279
Total assets
$
7,772,381
$
7,602,770
Liabilities, Redeemable Noncontrolling Interests and
Equity Current liabilities: Accounts payable
140,204
205,915
Accrued compensation
190,802
197,078
Deferred revenue
257,396
264,259
Accrued liabilities
220,704
219,758
Other current liabilities
198,517
204,575
Total current liabilities
1,007,623
1,091,585
Long-term debt, net and finance leases
2,678,472
2,707,531
Operating lease right-of-use liabilities
401,628
389,745
Deferred tax liabilities
207,404
215,582
Other long-term liabilities
177,252
174,822
Total liabilities
4,472,379
4,579,265
Redeemable noncontrolling interest
42,447
42,427
Equity: Preferred stock, $0.01 par value; 20,000 shares authorized;
no shares issued and outstanding
—
—
Common stock, $0.01 par value; 120,000 shares authorized; 51,370
shares issued and 51,266 shares outstanding as of July 1, 2023, and
50,944 shares issued and outstanding as of December 31, 2022
513
509
Additional paid-in capital
1,850,385
1,804,940
Retained earnings
1,633,052
1,432,901
Treasury stock, at cost, 104 and zero shares, as of July 1, 2023
and December 31, 2022, respectively
(23,978
)
—
Accumulated other comprehensive loss
(208,269
)
(262,057
)
Total equity attributable to common shareholders
3,251,703
2,976,293
Noncontrolling interests (nonredeemable)
5,852
4,785
Total equity
3,257,555
2,981,078
Total liabilities, redeemable noncontrolling interests and equity
$
7,772,381
$
7,602,770
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SCHEDULE 3 CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS (UNAUDITED) (in thousands) Six Months
Ended July 1, 2023 June 25, 2022 Cash flows
relating to operating activities Net income
$
203,397
$
205,890
Adjustments to reconcile net income to net cash provided by
operating activities: Depreciation and amortization
154,740
151,720
Stock-based compensation
29,730
29,549
Loss on debt extinguishment and amortization of other financing
costs
—
1,987
Deferred income taxes
(16,555
)
(14,684
)
Loss on venture capital and strategic equity investments, net
5,176
23,515
Loss on divestitures, net
563
—
Changes in fair value of contingent consideration arrangements
1,810
(15,420
)
Other, net
21,721
13,520
Changes in assets and liabilities: Trade receivables and contract
assets, net
(48,249
)
(117,642
)
Inventories
(32,671
)
(63,725
)
Accounts payable
(24,985
)
31,466
Accrued compensation
(7,648
)
(38,173
)
Deferred revenue
(6,796
)
27,641
Customer contract deposits
(17,519
)
16,100
Other assets and liabilities, net
(5,209
)
360
Net cash provided by operating activities
257,505
252,104
Cash flows relating to investing activities Acquisition of
businesses and assets, net of cash acquired
(50,166
)
(283,392
)
Capital expenditures
(174,258
)
(163,316
)
Purchases of investments and contributions to venture capital
investments
(22,689
)
(108,842
)
Proceeds from sale of investments
2,943
205
Other, net
(1,057
)
(4,774
)
Net cash used in investing activities
(245,227
)
(560,119
)
Cash flows relating to financing activities Proceeds from
long-term debt and revolving credit facility
281,796
2,180,511
Proceeds from exercises of stock options
15,719
15,571
Payments on long-term debt, revolving credit facility, and finance
lease obligations
(317,049
)
(1,856,262
)
Purchase of treasury stock
(23,978
)
(38,468
)
Payments of contingent consideration
(2,711
)
(10,356
)
Purchases of additional equity interests, net
—
(15,438
)
Other, net
—
(17,405
)
Net cash provided by (used in) financing activities
(46,223
)
258,153
Effect of exchange rate changes on cash, cash equivalents, and
restricted cash
1,508
10,756
Net change in cash, cash equivalents, and restricted cash
(32,437
)
(39,106
)
Cash, cash equivalents, and restricted cash, beginning of period
241,214
246,314
Cash, cash equivalents, and restricted cash, end of period
$
208,777
$
207,208
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SCHEDULE 4 RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)(1) (in
thousands, except percentages) Three Months
Ended Six Months Ended July 1, 2023 June 25,
2022 July 1, 2023 June 25, 2022 Research
Models and Services Revenue
$
209,948
$
186,410
$
409,714
$
362,952
Operating income
48,918
39,526
89,327
87,408
Operating income as a % of revenue
23.3
%
21.2
%
21.8
%
24.1
%
Add back: Amortization related to acquisitions
5,491
5,472
10,985
9,310
Severance
—
453
—
1,127
Acquisition related adjustments (2)
997
971
1,827
1,354
Total non-GAAP adjustments to operating income
$
6,488
$
6,896
$
12,812
$
11,791
Operating income, excluding non-GAAP adjustments
$
55,406
$
46,422
$
102,139
$
99,199
Non-GAAP operating income as a % of revenue
26.4
%
24.9
%
24.9
%
27.3
%
Depreciation and amortization
$
13,949
$
13,228
$
27,438
$
22,697
Capital expenditures
$
7,493
$
13,850
$
26,577
$
22,496
Discovery and Safety Assessment Revenue
$
663,457
$
591,917
$
1,325,810
$
1,136,176
Operating income
161,538
128,793
332,969
233,779
Operating income as a % of revenue
24.3
%
21.8
%
25.1
%
20.6
%
Add back: Amortization related to acquisitions
17,744
20,849
35,231
43,214
Severance
—
387
—
461
Acquisition related adjustments (2)
2,359
(2,591
)
2,603
(5,514
)
Site consolidation costs, impairments and other items (3)
1,492
2,287
4,297
2,356
Total non-GAAP adjustments to operating income
$
21,595
$
20,932
$
42,131
$
40,517
Operating income, excluding non-GAAP adjustments
$
183,133
$
149,725
$
375,100
$
274,296
Non-GAAP operating income as a % of revenue
27.6
%
25.3
%
28.3
%
24.1
%
Depreciation and amortization
$
43,124
$
44,626
$
85,574
$
91,415
Capital expenditures
$
48,326
$
41,578
$
113,510
$
90,508
Manufacturing Solutions Revenue
$
186,532
$
194,804
$
353,786
$
387,932
Operating income
24,403
62,503
26,509
108,871
Operating income as a % of revenue
13.1
%
32.1
%
7.5
%
28.1
%
Add back: Amortization related to acquisitions
11,125
11,373
23,146
23,271
Severance
2,517
271
3,433
378
Acquisition related adjustments (2)
2,182
(18,888
)
3,011
(14,746
)
Site consolidation costs, impairments and other items (3)
2,550
519
9,612
1,940
Total non-GAAP adjustments to operating income
$
18,374
$
(6,725
)
$
39,202
$
10,843
Operating income, excluding non-GAAP adjustments
$
42,777
$
55,778
$
65,711
$
119,714
Non-GAAP operating income as a % of revenue
22.9
%
28.6
%
18.6
%
30.9
%
Depreciation and amortization
$
19,523
$
18,000
$
39,607
$
36,482
Capital expenditures
$
10,862
$
24,431
$
32,600
$
47,259
Unallocated Corporate Overhead
$
(69,914
)
$
(43,411
)
$
(115,968
)
$
(93,869
)
Add back: Severance
—
167
—
1,254
Acquisition related adjustments (2)
4,799
3,014
7,002
7,130
Total non-GAAP adjustments to operating expense
$
4,799
$
3,181
$
7,002
$
8,384
Unallocated corporate overhead, excluding non-GAAP adjustments
$
(65,115
)
$
(40,230
)
$
(108,966
)
$
(85,485
)
Total Revenue
$
1,059,937
$
973,131
$
2,089,310
$
1,887,060
Operating income
164,945
187,411
332,837
336,189
Operating income as a % of revenue
15.6
%
19.3
%
15.9
%
17.8
%
Add back: Amortization related to acquisitions
34,360
37,694
69,362
75,795
Severance
2,517
1,278
3,433
3,220
Acquisition related adjustments (2)
10,337
(17,494
)
14,443
(11,776
)
Site consolidation costs, impairments and other items (3)
4,042
2,806
13,909
4,296
Total non-GAAP adjustments to operating income
$
51,256
$
24,284
$
101,147
$
71,535
Operating income, excluding non-GAAP adjustments
$
216,201
$
211,695
$
433,984
$
407,724
Non-GAAP operating income as a % of revenue
20.4
%
21.8
%
20.8
%
21.6
%
Depreciation and amortization
$
77,671
$
76,421
$
154,740
$
151,720
Capital expenditures
$
67,383
$
82,852
$
174,258
$
163,316
(1)
Charles River management believes that supplementary
non-GAAP financial measures provide useful information to allow
investors to gain a meaningful understanding of our core operating
results and future prospects, without the effect of often-one-time
charges and other items which are outside our normal operations,
consistent with the manner in which management measures and
forecasts the Company’s performance. The supplementary non-GAAP
financial measures included are not meant to be considered superior
to, or a substitute for results of operations prepared in
accordance with U.S. GAAP. The Company intends to continue to
assess the potential value of reporting non-GAAP results consistent
with applicable rules, regulations and guidance.
(2)
These adjustments are related to the evaluation and
integration of acquisitions, which primarily include transaction,
third-party integration, and certain compensation costs, fair value
adjustments associated with contingent consideration arrangements,
and an adjustment related to certain indirect tax liabilities.
(3)
Other items include certain third-party legal costs related
to (a) an environmental litigation related to the Microbial
business and (b) investigations by the U.S. government into the NHP
supply chain applicable to our Safety Assessment business.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SCHEDULE 5 RECONCILIATION OF GAAP EARNINGS TO NON-GAAP
EARNINGS (UNAUDITED)(1) (in thousands, except per share
data) Three Months Ended Six Months
Ended July 1, 2023 June 25, 2022 July 1,
2023 June 25, 2022 Net income attributable to
common shareholders
$
97,020
$
109,321
$
200,151
$
202,343
Add back: Non-GAAP adjustments to operating income (Refer to
previous schedule)
51,256
24,284
101,147
71,535
Venture capital and strategic equity investment losses, net
1,873
9,612
5,155
23,515
Loss on divestitures (2)
1,003
—
562
—
Other (3)
596
3,608
495
3,965
Tax effect of non-GAAP adjustments: Non-cash tax provision related
to international financing structure (4)
1,296
1,341
2,420
2,463
Tax effect of the remaining non-GAAP adjustments
(14,759
)
(6,293
)
(28,658
)
(20,813
)
Net income attributable to common shareholders, excluding non-GAAP
adjustments
$
138,285
$
141,873
$
281,272
$
283,008
Weighted average shares outstanding - Basic
51,216
50,823
51,157
50,732
Effect of dilutive securities: Stock options, restricted stock
units and performance share units
251
460
225
561
Weighted average shares outstanding - Diluted
51,467
51,283
51,382
51,293
Earnings per share attributable to common shareholders:
Basic
$
1.89
$
2.15
$
3.91
$
3.99
Diluted
$
1.89
$
2.13
$
3.90
$
3.94
Basic, excluding non-GAAP adjustments
$
2.70
$
2.79
$
5.50
$
5.58
Diluted, excluding non-GAAP adjustments
$
2.69
$
2.77
$
5.47
$
5.52
(1)
Charles River management believes that supplementary
non-GAAP financial measures provide useful information to allow
investors to gain a meaningful understanding of our core operating
results and future prospects, without the effect of often-one-time
charges and other items which are outside our normal operations,
consistent with the manner in which management measures and
forecasts the Company’s performance. The supplementary non-GAAP
financial measures included are not meant to be considered superior
to, or a substitute for results of operations prepared in
accordance with U.S. GAAP. The Company intends to continue to
assess the potential value of reporting non-GAAP results consistent
with applicable rules, regulations and guidance.
(2)
Adjustments included in 2023 relate to the gain on sale of
our Avian business, which was divested in 2022.
(3)
Amount included in 2023 relates to a final adjustment on the
termination of a Canadian pension plan. Amount included in 2022
relates to the sale of RMS Japan operations in October 2021 and a
reversal of an indemnification asset related to a prior
acquisition.
(4)
This amount relates to the recognition of deferred tax
assets expected to be utilized as a result of changes to the
Company's international financing structure.
CHARLES RIVER LABORATORIES
INTERNATIONAL, INC.
SCHEDULE 6
RECONCILIATION OF GAAP REVENUE
GROWTH
TO NON-GAAP REVENUE GROWTH,
ORGANIC (UNAUDITED) (1)
Three Months Ended July 1, 2023 Total CRL
RMS Segment DSA Segment MS Segment
Revenue growth, reported
8.9
%
12.6
%
12.1
%
(4.2
)%
Decrease (increase) due to foreign exchange
0.2
%
1.3
%
(0.1
)%
—
%
Contribution from acquisitions (2)
(0.2
)%
—
%
(0.3
)%
—
%
Impact of divestitures (3)
2.3
%
—
%
—
%
10.8
%
Non-GAAP revenue growth, organic (4)
11.2
%
13.9
%
11.7
%
6.6
%
Six Months Ended July 1, 2023 Total CRL RMS
Segment DSA Segment MS Segment Revenue
growth, reported
10.7
%
12.9
%
16.7
%
(8.8
)%
Decrease due to foreign exchange
1.1
%
1.9
%
1.0
%
0.9
%
Contribution from acquisitions (2)
(0.9
)%
(4.3
)%
(0.3
)%
—
%
Impact of divestitures (3)
2.3
%
—
%
—
%
10.3
%
Non-GAAP revenue growth, organic (4)
13.2
%
10.5
%
17.4
%
2.4
%
(1)
Charles River management believes that supplementary
non-GAAP financial measures provide useful information to allow
investors to gain a meaningful understanding of our core operating
results and future prospects, without the effect of often-one-time
charges and other items which are outside our normal operations,
consistent with the manner in which management measures and
forecasts the Company’s performance. The supplementary non-GAAP
financial measures included are not meant to be considered superior
to, or a substitute for results of operations prepared in
accordance with U.S. GAAP. The Company intends to continue to
assess the potential value of reporting non-GAAP results consistent
with applicable rules, regulations and guidance.
(2)
The contribution from acquisitions reflects only completed
acquisitions.
(3)
The Company sold our Avian business on December 20, 2022.
These adjustments represent the revenue from these businesses for
all applicable periods in 2023 and 2022.
(4)
Organic revenue growth is defined as reported revenue growth
adjusted for acquisitions, divestitures, and foreign exchange.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230809025737/en/
Investor Contacts: Todd Spencer Corporate Vice President,
Investor Relations 781.222.6455 todd.spencer@crl.com
Media Contact: Amy Cianciaruso Corporate Vice President, Chief
Communications Officer 781.222.6168 amy.cianciaruso@crl.com
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Charles River Laboratories (NYSE:CRL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024